Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carles Rafols Priu"'
Autor:
Francisco Marin, Marcelo Sanmartin Fernandez, Gonzalo Baron-Esquivias, Vivencio Barrios, Inaki Lekuona, Alejandro I Perez-Cabeza, Jaime Masjuan, Esther Recalde del Vigo, Jose Manuel Vazquez Rodriguez, Roman Freixa-Pamias, Vanessa Roldan Schilling, Fernando Arribas, Carles Rafols Priu, Manuel Anguita Sanchez
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 3 (2023)
Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospec
Externí odkaz:
https://doaj.org/article/eda29beddbb14fddb75450f8299c618d
Autor:
Francisco Marin, Marcelo Sanmartín Fernández, Iñaki Lekuona, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Jaime Masjuan, Alejandro I Pérez-Cabeza, Vanessa Roldán Schilling, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Manuel Anguita Sánchez
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1173-1184
Objective: To analyze the effectiveness and safety of rivaroxaban in patients with atrial fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly compared with those of ROCKET-AF, eight other Spanish observatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57fa3ee68744398d8d193acaeb1e0851
https://doi.org/10.2217/cer-2022-0111
https://doi.org/10.2217/cer-2022-0111
Autor:
Marcelo Sanmartín Fernández, Manuel Anguita Sánchez, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, María Asunción Esteve-Pastor, Roman Freixa-Pamias, Iñaki Lekuona, Alejandro I. Pérez-Cabeza, Isabel Ureña, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Francisco Marin
Publikováno v:
Cardiology Journal. 29:601-609
The aim of the study was to evaluate the performance of the 2MACE in patients with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE.This was a post-authorization and observational study of AF adults treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bab2e783b7194357d4a445e71d56f35
https://doi.org/10.5603/cj.a2022.0044
https://doi.org/10.5603/cj.a2022.0044
Autor:
Manuel Anguita Sánchez, Francisco Marín, Jaime Masjuan, Juan Cosín-Sales, José Manuel Vázquez Rodríguez, Vivencio Barrios, Gonzalo Barón-Esquivias, Iñaki Lekuona, Alejandro I. Pérez-Cabeza, Román Freixa-Pamias, Francisco Javier Parra Jimenez, Mohamed Monzer Khanji Khatib, Carles Rafols Priu, Marcelo Sanmartín Fernández
Publikováno v:
Cardiology journal.
The aim of this study was to analyze the impact of the presence of heart failure (HF) on the clinical profile and outcomes in patients with atrial fibrillation (AF) anticoagulated with rivaroxaban.Observational and non-interventional study that inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d8057abbda8586eb12b98fb648692d
https://pubmed.ncbi.nlm.nih.gov/36200548
https://pubmed.ncbi.nlm.nih.gov/36200548